{
    "clinical_study": {
        "@rank": "134715", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give ABT-378/ritonavir\n      combination plus nevirapine plus two nucleoside transcriptase inhibitors to HIV-infected\n      patients who previously have taken protease inhibitors. This study also examines how the\n      body handles this combination of anti-HIV drugs."
        }, 
        "brief_title": "A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n        - Antiretroviral regimen containing a protease inhibitor and one or two nucleoside reverse\n        transcriptase inhibitors that has not changed in the last 12 weeks.\n\n        Patients must have:\n\n        - HIV infection with plasma HIV RNA of at least 1,000 copies/ml and less than or equal to\n        100,000 copies/ml at screening.\n\n        Prior Medication:\n\n        Allowed:\n\n        Naive to or has had less than 8 weeks of at least one nucleoside reverse transcriptase\n        inhibitor and an acceptable regimen of two nucleoside reverse transcriptase inhibitors.\n\n        Exclusion Criteria\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Medications that are contraindicated with ABT-378/ritonavir for the duration of the\n             study, such as midazolam, triazolam, terfenadine, astemizole, cisapride, pimozide,\n             ergotamine and dihydroergotamine.\n\n          -  Over-the-counter medicine or alcohol, without knowledge or permission of the\n             investigator.\n\n        Patients with the following prior conditions are excluded:\n\n          -  Evidence of acute illness determined by vital signs, physical examination, or\n             laboratory results.\n\n          -  Clinically significant abnormal ECG results.\n\n          -  Positive test result for drug abuse with the exception of cannabis, unless the\n             investigator anticipates cannabis use will interfere with compliance with the study.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Investigational drugs with the exception of Amprenavir within 28 days prior to the\n             initiation of study dosing.\n\n          -  Treatment with a non-nucleoside reverse transcriptase inhibitor.\n\n          -  Treatment with a protease inhibitor different from the current protease inhibitor for\n             more than 6 weeks prior to current regimen.\n\n          -  Treatment with more than one protease inhibitor concurrently.\n\n        Risk Behavior:\n\n        Excluded:\n\n          -  Active substance abuse, alcohol abuse, psychiatric illness.\n\n          -  Presumption, by investigator, of poor compliance to regimen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004580", 
            "org_study_id": "285B", 
            "secondary_id": "M97-765"
        }, 
        "intervention": [
            {
                "intervention_name": "Lopinavir/Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nevirapine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Protease Inhibitors", 
                "Ritonavir", 
                "Lopinavir", 
                "HIV Protease Inhibitors", 
                "Nevirapine", 
                "Reverse Transcriptase Inhibitors"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "Nevirapine", 
            "HIV Protease Inhibitors", 
            "Ritonavir", 
            "Reverse Transcriptase Inhibitors"
        ], 
        "lastchanged_date": "February 19, 2009", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beverly Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90211"
                    }, 
                    "name": "Pacific Oaks Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "San Francisco Gen Hosp / UCSF AIDS Program"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "Univ of Colorado Health Sciences Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "AIDS Research Consortium of Atlanta"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush Presbyterian St Lukes Med Ctr / Sect Infect Dise"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "Univ North Carolina at Chapel Hill / Dept of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke Univ Med Ctr / Infectious Disease Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "452670405"
                    }, 
                    "name": "Univ of Cincinnati Med Ctr / Holmes Div Mail Loc 0405"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "152132582"
                    }, 
                    "name": "Univ of Pittsburgh"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Annandale", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22203"
                    }, 
                    "name": "Infectious Disease Physicians Inc"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I/II Study of ABT-378/Ritonavir in Protease Inhibitor Experienced HIV-Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004580"
        }, 
        "source": "Abbott", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2009"
    }, 
    "geocoordinates": {
        "AIDS Research Consortium of Atlanta": "33.749 -84.388", 
        "Duke Univ Med Ctr / Infectious Disease Clinic": "35.994 -78.899", 
        "Infectious Disease Physicians Inc": "38.83 -77.196", 
        "Pacific Oaks Research": "34.074 -118.4", 
        "Rush Presbyterian St Lukes Med Ctr / Sect Infect Dise": "41.878 -87.63", 
        "San Francisco Gen Hosp / UCSF AIDS Program": "37.775 -122.419", 
        "Univ North Carolina at Chapel Hill / Dept of Medicine": "35.913 -79.056", 
        "Univ of Cincinnati Med Ctr / Holmes Div Mail Loc 0405": "39.103 -84.512", 
        "Univ of Colorado Health Sciences Ctr": "39.739 -104.985", 
        "Univ of Pittsburgh": "40.441 -79.996"
    }
}